Tasipimidine

Tasipimidine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names ODM-105 and ORM-19695), sold under the brand name Tessie, is an α₂-adrenergic receptor agonist which is approved for the short-term treatment of fear and anxiety in dogs.^[1][4] It is also under development for the treatment of insomnia in humans.^[2][3][5] The drug is used as an oral solution in dogs,^[1] whereas its route of administration for humans is unspecified.^[3]

Trade namesTessie

Other namesODM-105; ODM105; ORM-19695; ORM19695

Routes of
administrationDogs: Oral^[1][2]
Humans: unspecified^[3]

Drug classα_2A-Adrenergic receptor agonist; Anxiolytic; Sedative; Hypnotic

Quick facts Clinical data, Trade names ...

Tasipimidine

Clinical data
Trade names	Tessie
Other names	ODM-105; ODM105; ORM-19695; ORM19695
Routes of administration	Dogs: Oral[1][2] Humans: unspecified[3]
Drug class	α2A-Adrenergic receptor agonist; Anxiolytic; Sedative; Hypnotic
Identifiers
IUPAC name 2-(5-methoxy-3,4-dihydro-1H-isochromen-1-yl)-4,5-dihydro-1H-imidazole
CAS Number	1465908-70-6
PubChem CID	71767208
ChemSpider	64835228
UNII	QX8MJH6HGK
KEGG	D11635
ChEMBL	ChEMBL4594267
Chemical and physical data
Formula	C13H16N2O2
Molar mass	232.283 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC=CC2=C1CCOC2C3=NCCN3
InChI InChI=1S/C13H16N2O2/c1-16-11-4-2-3-10-9(11)5-8-17-12(10)13-14-6-7-15-13/h2-4,12H,5-8H2,1H3,(H,14,15) Key:GHIKYGQWBRHEGU-UHFFFAOYSA-N

Close

The drug acts as a potent and selective full agonist of the human α_2A-adrenergic receptor.^[2] Conversely, it is a much weaker agonist of the rodent α_2B-, α_2C-, and α_2D-adrenergic receptors.^[2] In addition, it shows only low affinity for α₁-adrenergic receptors, where it appears to act as a partial agonist.^[2] Tasipimidine produces anxiolytic, sedative, hypolocomotor, hypotensive, and bradycardic effects in animals.^[2]

Tasipimidine is under development for use in humans by Orion Corporation.^[3][5] As of October 2024, it is in phase 2 clinical trials for this indication.^[3][5] The drug is or was also under development for the treatment of psychiatric disorders in humans, but no recent development for this indication has been reported.^[3] It has reached phase 1 trials for psychiatric disorders.^[3] Tasipimidine was approved for treatment of fear and anxiety in dogs in the European Union in 2021.^[1]